Palatin and FDA Reach Agreement on Path to NDA Submission, including Trial Design, Endpoints, Interim Assessment, and Patient Population On Track to Initiate Phase 3 Study Calendar Q4 2021 with Data Expected Calendar 2H 2022 Jun 29, 2021, 07:30 ET CRANBURY, N.J., June 29, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) a …
Michael B. Raizman, M.D. – Chief Medical Officer James E. Hattersley – Senior Vice President, Business Development J. Don Wang, Ph.D. – Vice President, Product Development Jun 28, 2021, 07:30 ET CRANBURY, N.J., June 28, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that …
Palatin Announces New Additions to Its Senior Leadership Team Read More »
– Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Proposals 1, 2, and 4 were approved at the Annual Meeting – Scheduled to Reconvene July 8, 2021, 9:00 a.m. Eastern Daylight Time Jun 10, 2021, 07:30 ET CRANBURY, N.J., June 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) …
Palatin Announces Adjournment of Annual Meeting of Stockholders Read More »
